Oncology · Endometrial CancerOtherclinicalmid-term

RBM15B/FOXM1/AURKA/TPX2 axis identified as key driver in endometrial cancer progression

Importance8/ 10

ActionInvestigate

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 12:33:39 AM

Assessment confidence: 65% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The identification of the RBM15B/FOXM1/AURKA/TPX2 axis as a key driver in endometrial cancer progression presents a significant opportunity for therapeutic intervention. This novel pathway could reshape treatment strategies and address unmet medical needs in oncology. Regulatory context from MHRA (MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer) supports the near-term read. Assessment grounded in 25 ranked evidence items (11 high-relevance).

Strategic Assessment

Pharma companies should consider developing inhibitors targeting the RBM15B/FOXM1/AURKA/TPX2 pathway to address unmet needs in endometrial cancer treatment. The strongest clinical anchor is HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer (ClinicalTrials.gov), sponsor/company relevance (roche). In Oncology · Endometrial Cancer, 5 regulatory and 4 competitive items passed relevance filtering for endometrial cancer patients.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC (Humanexa Signals) — sponsor/company relevance (pfizer). Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial. This finding highlights a novel pathway that could be targeted for therapeutic intervention in endometrial cancer, potentially impacting existing treatment strategies.

Regulatory Outlook

Regulatory risk is concentrated around MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer (MHRA). Regulatory pathway relevance (bla). Relevant agencies in corpus: MHRA, FDA. Targeting this newly identified pathway may require navigating regulatory pathways for new drug approvals, which could impact timelines for bringing new therapies to market.

Key Risks

Elevated medium regulatory exposure for endometrial cancer patients could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

Developing inhibitors targeting this pathway could lead to new revenue streams and enhance market share in the oncology segment, particularly for companies focused on endometrial cancer therapies.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Upside for endometrial cancer patients may improve if HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor developments in targeted therapies against the RBM15B/FOXM1/AURKA/TPX2 pathway and clinical trial outcomes.
Timeline shift beyond mid term would change urgency.
Outcome from Withdrawn | Cancer Accelerated Approvals would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer
MHRAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
RNA Modifications as Key Regulators in Cancer Translational Control and Therapeutic Strategies
Humanexa Signalsmedium relevance
Moderate corpus alignment
Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma
Humanexa Signalsmedium relevance
Moderate corpus alignment

RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
STARD10 promotes progression of HER2+ breast cancer and intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling axis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The "oral-gut axis" transmission of microorganisms in colorectal cancer: Insights from Peptostreptococcus' perspective.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
MicroRNA-6833-3p drives prostate cancer progression and stemness by targeting the NUMB-mediated NOTCH signaling pathway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
FTO-mediated m(6)A demethylation of BCL6 promotes gastric cancer progression by suppressing ferroptosis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Dectin-1 signaling promotes Galectin-3 shedding and expansion of immunosuppressive CD71+ erythroid cells in breast cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
NSUN2 mediates SALL2 m5C methylation to inhibit ferroptosis and promote breast cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

endometrial cancer patients
existing endometrial cancer treatments
pharmaceutical companies developing oncology therapies
RBM15B/FOXM1/AURKA/TPX2 pathway

Commercial impact

high

Developing inhibitors targeting this pathway could lead to new revenue streams and enhance market share in the oncology segment, particularly for companies focused on endometrial cancer therapies.

Regulatory impact

medium

Targeting this newly identified pathway may require navigating regulatory pathways for new drug approvals, which could impact timelines for bringing new therapies to market.

What to watch

Monitor developments in targeted therapies against the RBM15B/FOXM1/AURKA/TPX2 pathway and clinical trial outcomes.

Recommended action

Investigate

Assign analyst review and cross-reference against active portfolio assets.